

INFORMATION DISCLOSURE STATEMENT

pplicant

Goddard, et al. (as amended)

App. No

: 10/063,549

Filed

: May 2, 2002

For

POLYPEPTIDES ENCODED BY A

NUCLEIC ACID OVEREXPRESSED

IN ESOPHAGEAL AND KIDNEY TUMOR (as amended)

Examiner

Patricia Ann Duffy

Art Unit

1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 23, 2005

(Date)

AnneMarie Kaiser, Reg. No. 37,649

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 45 references to be considered by the Examiner. Also enclosed are 31 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement. Please note that reference No. 1 (Jacobs) is only being cited to correct a typographical error in the IDS which was filed September 6, 2002.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

6

Dated:

06/27/2005 EAREGAY1 00000111 10063549

01 FC:1806

180.00 OP

Jun 23 2009

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record

Customer No. 30,313

(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 10/063,549

Filing Date May 2, 2002

First Named Inventor Goddard, et al. (as amended)

Art Unit 1645

Examiner Patricia Ann Duffy

Multiple sheets used when necessary)

SHEET 1 OF 3 Attorney Docket No. GNE.3230R1C34

/	<u> </u>	SHEET TOF 3	At	torney Docket No.	GNE.3230R1	1034
JUN 2 7	2005			···	=1000	
k I		U.S. PATENT DOCUMENTS				
Etaminer Install BAD	MANUE OF	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee	or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,536,637	07-16-1996	Jacobs		
	2	6,025,156	02-15-2000	Gwynn, et al.		
	3	6,124,433	09-26-2000	Falb, et al.		
	4	6,156,500	12-05-2000	Falb, Dean		
	5	6,162,604	12-19-2000	Jacob, Chaim O.		
	6	6,228,582	05-08-2001	Rodier, et al.		
	7	6,395,306	05-28-2002	Cui, et al.		
	8	6,414,117	07-02-2002	Levinson, D. A.		•
	9	6,465,185	10-15-2002	Goldfine, et al.		
	10	6,498,235	12-24-2002	Sheppard, et al.	·	
	11	6,562,343	05-13-2003	Levinson, D. A.		
	12	6,645,499	11-11-2003	Lal, et al.		
	13	6,730,502	05-04-2004	Van Hijum, et al.		
	14	6,737,522	05-18-2004	Sundick, et al.		Jan 11

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	15	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell, 3rd Edition</i> , pp. 403-404, 453. New York: Garland Publishing.	
	16	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	17	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. <i>Blood</i> , 87(12):5257-5268.	
	18	CHEN, et al. 2002. Discordant Protein and mRNA Expression in Lung Adenocarcinomas. <i>Molecular & Cellular Proteomics 1.4</i> , 304-313.	
	19	Database Search, DNA Sequence Alignments [BLASTN 2.2.1[July-12-2001], NCBI]	
	20	Database Search, Protein Sequence Alignments [BLASTN 2.2.1[July-12-2001], NCBI]	
	21	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal, Vol. 15, No. 16,</i> pp. 4392-4401.	

Examiner	Signature
----------	-----------

Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

	INFORMATION DISCLOSURE
P	ESTATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 2 OF 3

Application No.	10/063,549
Filing Date	May 2, 2002
First Named Inventor	Goddard, et al. (as amended)
Art Unit	1645
Examiner	Patricia Ann Duffy
Attorney Docket No.	GNE.3230R1C34

10H 27 7005 NON PATENT LITERATURE DOCUMENTS WA TRAI Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite Examiner T^1 item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials No. number(s), publisher, city and/or country where published. GÖKMEN-POLAR, et al., February 2001, Elevated Protein Kinase C BII Is an Early Promotive Event in Colon Carcinogenesis, Cancer Research, Vol. 61, pp.1375-1381. GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. Blood, 23 73(8):2081-2085. GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. 24 Molecular and Cellular Biology, 1720-1730. HANASH, S. 2003. Making sense of microarray data to classify cancer. The Pharmacogenomics 25 Journal, 3:308-311. HANASH, S. March 2005. Integrated global profiling of cancer. Nature Reviews, Applied Proteomics Collection, pp. 9-14. 27 HANCOCK, W. S. 2004. Do We Have Enough Biomarkers? Journal of Proteome Research, 3(4):685. HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. Pathology Associates 28 Medical Laboratories. HAYNES, et al., 1998. Proteome analysis: Biological assay or data archive? Electrophoresis, 29 Vol. 19, pp. 1862-1871. HU, et al. 2003. Analysis of Genomic and Proteomic Data Using Advanced Literature Mining. 30 Journal of Proteome Research, Vol. 2, pp. 405-412. HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns. Cancer Research, 62:6240-6245. JANG A. Hill RP, Sept. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. Clin. Exp. Metastasis 15(5): pp. 469-483 KONOPKA, et al. June 1986. Variable Expression of the Translocated c-abl Oncogene in Philadelphia-Chromosome-Positive B-Lymphoid Cell Lines from Chronic Myelogenous 33 Leukemia Patients, National Academy of Sciences of the United States of America, Vol. 83. No. 11, pp. 4049-4052 LEWIN, B. 1994. Oncogenes: Gene Expression and Cancer, Chap. 39, pp.1196-1201. Genes V. New York: Oxford University Press. LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. Genes VI. New York: 35 Oxford University Press. MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in 36 acute lymphocytic leukemia with eosinophilia. Blood, 76(2):285-289. MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. Molecular Cancer Therapeutics, 1:971-979. OHARA, et al. 2001. Directional cDNA library construction assisted by the in vitro 38

Examiner Signature	Date Considered

recombination reaction. Nucleic Acids Research, Vol. 29, No e22, pp.1-8.

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $[\]mathsf{T}^\mathsf{1}$ - Place a check mark in this area when an English language $\mathsf{Translation}$ is attached.

	Application No.	10/063,549
INFORMATION DISCLOSURE	Filing Date	May 2, 2002
STATEMENT BY ADDITIONT	First Named Inventor	Goddard, et al. (as amended)
STATEMENT BY APPLICANT	Art Unit	1645
Aultinia shoots used when necessary)	Examiner	Patricia Ann Duffy
SHEET 3 OF 3	Attorney Docket No.	GNE.3230R1C34

	7	NON PATENT LITERATURE DOCUMENTS	
Exclamiter Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T¹
	39	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular & Cellular Proteomics</i> , 1:37-45.	
,	40	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	41	POWELL, et al. Oct. 1998. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics, Vol.5:</i> pp. 411-421.	
	42	SINGLETON, et al. 1992. Clinical and pathologic significance of the c- <i>erb</i> B-2 (<i>HER-2/neu</i>) oncogene. <i>Pathol. Annu</i> , 1(27):165-190.	
	43	VALLEJO, et al. Dec. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. <i>Biochimie</i> 82(12): 1129-33.	
	44	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.	
	45	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World Journal of Surgical Oncology, 2:13.	

1785917_1 062305

Examiner Signature

Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.